Giulia Dondi

ORCID: 0000-0001-8393-1799 · 12 papers in corpus
2026
·doi:10.1016/j.ijgc.2025.103950
diagnostic-accuracy 2025
·doi:10.3390/app15063070

Background/Objectives: The aim of this study was the early identification of endometriosis-associated ovarian cancer (EAOC) versus non-endometriosis associated ovarian cancer (NEOC) or non-cancerous tissues using pre-surgery contrast-enhanc…

other 2025
Translational oncology ·doi:10.1016/j.tranon.2025.102367

BACKGROUND: Endometriosis (EMS) is a chronic, gynecological condition affecting 6-10 % of reproductive-age women. While these lesions are benign, ovarian EMS presents cancer-like features, and can progress to endometriosis-correlated ovaria…

2025
·doi:10.1016/j.ijgc.2024.100413
observational 2025
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society ·doi:10.1016/j.ijgc.2025.101634

OBJECTIVE: This study aimed to describe 2 types of endometriosis-associated ovarian cancer: those with transitional elements (atypical endometriosis and borderline tumors) termed endometriosis-correlated or incidental benign endometriosis v…

2024
·doi:10.1136/ijgc-2024-esgo.794
2024
·doi:10.1136/ijgc-2024-esgo.62
2024
·doi:10.1136/ijgc-2024-esgo.623
2024
·doi:10.1016/j.ejmp.2024.103598
observational 2020
International journal of molecular sciences ·doi:10.3390/ijms21197188

Since 2016, our hospital has applied tumor testing with immunohistochemistry (IHC) in endometrial cancer in order to detect mutations of mismatch repair genes (MMR). All cases with MMR deficiency proteins expression are sent for genetic tes…

case-report 2018
Clinical Medicine Insights. Oncology ·doi:10.1177/1179554918782477

Adenosarcomas are the rarest form of uterine sarcomas, and clinical experience with their management is still limited. Here, we reported 7 patients with uterine adenosarcoma referred to our institution, focusing on main pathologic features,…

observational 2013
Journal of ovarian research ·doi:10.1186/1757-2215-6-11

BACKGROUND: The FSH starting dose is usually chosen according to women's age, anamnesis, clinical criteria and markers of ovarian reserve. Currently used markers include antral follicle count (AFC), which is considered to have a very high p…